Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary: Objectives To assess (i) the influence of Thyrotropin (TSH) suppression at a level of <0·1 mU/l and (ii) whether FT3 and FT4 levels have a prognostic significance independently of TSH values with regard to survival in patients with differentiated thyroid carcinoma (DTC) and distant metastases. Patients and methods In a retrospective patient chart study, we reviewed survival in 157 DTC patients with distant metastases treated between September 1985 and 1 July 2010. Patients with at least three available FT3 and FT4 values during TSH suppression were eligible. Results Fifty‐three of 157 patients died from DTC. DTC‐specific survival was significantly better in patients with a median TSH level ≤0·1 mU/l (median survival 15·8 years) than those with a non‐suppressed TSH level (median survival 7·1 years; P < 0·001). However, there was no further improvement in survival caused by TSH suppression to a level ≤0·03 mU/l (P = 0·24). FT3 and FT4 levels were also significantly associated with poorer survival; of these, only the prognostic value of FT3 was independent from that of TSH levels. Conclusion The care of patients with DTC and distant metastases is like walking an endocrinological tightrope: non‐suppressed TSH levels, that is, >0·1 mU/l, are associated with an impaired prognosis. There is, however, no prognostic benefit from suppressing TSH to levels lower than 0·1 mU/l. On the contrary, an improvement in prognosis might be achieved by keeping FT3 levels as low as possible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Applications of a New Chemiluminometric Thyrotropin Assay to Subnormal Measurement*
SPENCER, C. A., LoPRESTI, J. S., PATEL, A., GUTTLER, R. B., EIGEN, A., SHEN, D., GRAY, D., & NICOLOFF, J. T. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-2-453 · Cited by 371
Spencer, C. A., Schwarzbein, D., Guttler, R. B., LoPresti, J. S., & Nicoloff, J. T. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.2.8432796 · Cited by 126
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Treatment with thyroid hormone
Biondi, B., & Wartofsky, L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1083 · Cited by 259
Carhill, A. A., Litofsky, D. R., Ross, D. S., Jonklaas, J., Cooper, D. S., Brierley, J. D., Ladenson, P. W., Ain, K. B., Fein, H. G., Haugen, B. R., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1346 · Cited by 184
Wang, L. Y., Smith, A. W., Palmer, F. L., Tuttle, R. M., Mahrous, A., Nixon, I. J., Patel, S. G., Ganly, I., Fagin, J. A., & Boucai, L. (2015) · Thyroid · doi:10.1089/thy.2014.0287 · Cited by 161
“Thus, TSH suppression has been associated with increased survival or delayed progression to recurrence, especially in high-risk patients (21,22).”
Metadata
- Authors
- Diessl, S., Holzberger, B., Mäder, U., Grelle, I., Smit, J. W. A., Buck, A. K., Reiners, C., & Verburg, F. A.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2012-03-07
- Volume
- 76
- Issue
- 4
- Pages
- 586-592
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2125517852
- Cited by
- 86
- References
- 2
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.